Order results by:
| Issue | Title | |
| Vol 10, No 1 (2017) | THE USE OF QALY AS AN INTEGRAL MEASURE OF EFFECTIVENESS IN THE EVALUATION OF MEDICAL TECHNOLOGIES | Abstract similar documents |
| N. Z. Musina, V. K. Fedyaeva | ||
| "... This report addresses the ways of calculating QALY (Quality-adjusted life-year). OutsideRussia ..." | ||
| Vol 5, No 3 (2012) | COST-UTILITY ANALYSIS PATIENTS WITH LOW BACK PAIN AFTER TREATMENT INTRAOSSEOUS BLOCKADES | Abstract similar documents |
| M. V. Yakovlev, A. U. Kulikov, E. L. Sokov, I. E. Kornilova | ||
| "... with the Oswestry low back pain disability questionnaire, converted into utilities and transformed into quality ..." | ||
| Vol 6, No 3 (2013) | METHODOLOGICAL BASIS OF STANDARD GAMBLE METHOD USAGE IN QUALITY OF LIFE ASSESSMENT IN PHARMACOECONOMIC RESEARCHES | Abstract similar documents |
| R. I. Yagudina, A. Ju. Kulikov, D. T. Ugrekhelidze | ||
| "... Utility assessment is one of the most important stages of pharmacoeconomic analysis. Most ..." | ||
| Vol 6, No 4 (2013) | Фармакоэкономический анализ использования лираглутида в составе комбинированной терапии в лечении сахарного диабета 2-го типа | Abstract similar documents |
| A. Yu. Kulikov, I. V. Novikov | ||
| "... and effectiveness in terms of QALY are compared for liraglutide, glimepiride and rosiglitazone, all in combination ..." | ||
| Vol 6, No 3 (2013) | COST-UTILITY ANALYSIS OVER USE OF TYROSINE KINASE INHIBITORS (TASIGNA AND GLEEVEC) FOR TREATMENT OF CHRONIC MYELOID LEUKEMIA IN THE CHRONIC PHASE AS FIRST-LINE THERAPY FOR DE NOVO PATIENTS | Abstract similar documents |
| R. I. Yagudina, A. Yu. Kulikov, I. A. Komarov | ||
| "... -effectiveness analysis and cost-utility analysis on the basis of two tyrosine kinase inhibitors in Russian ..." | ||
| Vol 9, No 1 (2016) | COMPARATIVE CLINICAL AND ECONOMIC ANALYSIS OF THE INTENSIFICATION THERAPY IN PATIENTS WITH UNCONTROLLED DIABETES TYPE 2 USING BASAL INSULIN OR DAPAGLIFLOZIN | Abstract similar documents |
| V. I. Petrov, S. V. Nedogoda, M. Yu. Frolov, A. S. Salasyuk, I. N. Barykina, V. O. Smirnova, V. Yu. Khripaeva | ||
| "... according to standard pharmacoeconomic methods: cost-utility analysis (CUA), budget impact analysis (BIA ..." | ||
| Vol 5, No 2 (2012) | METHODOLOGY OF COST-UTILITY ANALYSIS IN PHARMACOECONOMICSTUDIES | Abstract similar documents |
| R. I. Yagudina, I. V. Sorokovikov | ||
| "... pharmacoeconomic cost-utility analysis – CUA is at third place by popularity (10% of studies ..." | ||
| Vol 10, No 2 (2017) | COST-EFFECTIVENESS OF VILANEROL / UMECLIDINIUM VERSUS TIOTROPIUM IN SEVERE AND VERY SEVERE COPD | Abstract similar documents |
| E. G. Kosolapov, F. S. Kochenkov, N. L. Pogudina, D. V. Blinov | ||
| "... and extremely severe COPD (FEV1 <50%, CAT ≥10, mMRC ≥2, with severe symptoms). QALY (quality-adjusted life-year ..." | ||
| Vol 8, No 2 (2015) | REASONS FOR DIFFICULTY OF THE PHARMACOECONOMIC ANALYSIS FOR ORPHAN DRUGS. WAYS FOR SOLUTIONS | Abstract similar documents |
| Andrey Vladislavovich Pavlysh, Aleksei Sergeevich Kolbin, Roman Andreevich Gapeshin, Stanislav Mikhailovich Malyshev | ||
| "... need a specific approach due to high costs of the drugs and limited sample size. Cost-utility analysis ..." | ||
| Vol 6, No 2 (2013) | COST-EFFECTIVENESS ANALYSIS OVER USE OF TYROSINE KINASE INHIBITORS (TASIGNA AND GLEEVEC) FOR TREATMENT OF CHRONIC MYELOID LEUKEMIA IN THE CHRONIC PHASE AS FIRST-LINE THERAPY FOR DE NOVO PATIENTS | Abstract similar documents |
| R. I. Yagudina, A. Yu. Kulikov, I. A. Komarov | ||
| "... полного цитогенетического ответа (ПЦО) на протяжении одного года из расчета на одного пациента с ХФ ХМЛ ..." | ||
| Vol 5, No 3 (2012) | PHARMACOECONOMIC EVALUATION OF THE MEDICINAL PRODUCTS ERLOTINIB, DOCETAXEL, PEMETREXED AND GEFITINIB IN THE SECOND-LINE TREATMENT OF LOCALLY-ADVANCED OR METASTATIC NON-SMALL-CELL LUNG CANCER | Abstract similar documents |
| A. U. Kulikov | ||
| Vol 5, No 3 (2012) | PHARMACOECONOMIC STUDY OF PRIMARY OPEN-ANGLE GLAUCOMA TREATMENT WITH FIX COMBINATION OF CARBONIC ANHYDRASE INHIBITORS AND BETABLOCKERS | Abstract similar documents |
| M. V. Protsenko | ||
| "... of carbonic anhydrise inhibitors and betablockers by mean of cost-utility, willingness-to-pay, cost ..." | ||
| Vol 7, No 2 (2014) | CLINICAL AND ECONOMIC EVALUATION OF IVABRADINE USE IN STABLE ANGINA IN TERMS OF REPUBLIC OF BELARUS HEALTH CARE SYSTEM | Abstract similar documents |
| I. N. Kozhanova, I. S. Romanova, L. N. Gavrilenko, A. V. Patseev, M. M. Sachek | ||
| "... -effectiveness” and “cost-utility” analyses have been used. The target population of patients suffering from ..." | ||
| Vol 11, No 4 (2018) | International experience in determining the cost-effectiveness thresholds | Abstract similar documents |
| T. P. Bezdenezhnykh, N. Z. Musina, V. K. Fedyaeva, T. S. Tepcova, V. A. Lemeshko, V. V. Omelyanovsky | ||
| "... , which is represented by quality-adjusted life year (QALY) in most counties. However,PolandandBrazilallow ..." | ||
| Vol 12, No 3 (2019) | Availability and Pharmacoeconomics of Insulin Therapy in Countries with the Largest Number of Diabetics | Abstract PDF (Eng) similar documents |
| S. V. Ponomarenko | ||
| Vol 12, No 3 (2019) | Approaches to assessing the demand for medical personnel in the Russian Federation | Abstract similar documents |
| S. N. Tishkina , T. G. Alkhasov , D. V. Lukyantseva , T. P. Bezdenezhnykh | ||
| "... которых относятся расчет потребности во врачебных кадрах и мероприятия по привлечению кадров (целевые ..." | ||
| Vol 9, No 1 (2016) | COST-EFFECTIVENESS ANALYSIS OF BRENTUXIMAB VEDOTIN IN ADULTS WITH RELAPSED OR REFRACTORY HODGKIN’S LYMPHOMA | Abstract similar documents |
| G. R. Khachatryan, D. V. Fedyaev, M. V. Avxentyeva, V. S. Dombrovskiy | ||
| "... + alloSCT vs Ch ± RT per life year (LY) and quality-adjusted life year (QALY) was calculated. In the second ..." | ||
| Vol 13, No 2 (2020) | Review of calculation methods, procedures for registration and re-registration of producer prices of medicines in the countries of the Eurasian Economic Union | Abstract similar documents |
| A. A. Leshkevich, D. S. Yurochkin, Z. M. Golant, I. A. Narkevich | ||
| Vol 6, No 2 (2013) | PHARMACOECONOMIC MODELING OF ANTIRETROVIRAL DRUGS USE DURING TREATMENT OF HIV INFECTION | Abstract similar documents |
| V. A. Chibilyaev, A. Yu. Kulikov, R. I. Yagudina | ||
| "... (QALY) is growing, which makes it advisable to use ART in health care on larger scale. ..." | ||
| Vol 11, No 3 (2018) | Determination of a willingness-to-pay threshold and decision-making in financing the healthcare technologies | Abstract similar documents |
| T. S. Teptsova, T. P. Bezdenezhnyh, V. K. Fedyaeva, N. Z Musina, G. R. Hachatryan, V. V. Tarasov | ||
| "... prevented (DALY) and the cost of quality-adjusted life-year saved (QALY) were determined by the suppling ..." | ||
| Vol 6, No 2 (2013) | FIRST RUSSIAN TYPE 2 DIABETES MELLITUS SIMULATION MODEL WITH DISCREET EVENTS MODELING. HEALTH-ECONOMIC ANALYSIS | Abstract similar documents |
| A. S. Kolbin, O. K. Khmelnitskiy, A. A. Kurylev, Yu. E. Balykina, M. A. Proskurin, E. P. Kolpak, M. V. Bure | ||
| "... of type 2 DM therapies liraglutide (Victoza®) was considered as the cost-effective strategy with ICER/QALY ..." | ||
| Vol 5, No 3 (2012) | CLINICAL AND ECONOMIC BENEFITS OF HUMAN INSULIN ANALOGUESUSE | Abstract similar documents |
| E. E. Arinina, M. A. Rashyd | ||
| "... pharmacoeconomic analyses: «cost – effectiveness,» «cost – utility» and « budget impact». Analysis included ..." | ||
| Vol 11, No 3 (2018) | Ocrelizumab – a monoclonal antibody – in the treatment of adult patients with multiple sclerosis: a systematic review | Abstract similar documents |
| D. L. Klabukova, M. E. Holownia-Voloskova, M. V. Davydovskaya, T. N. Ermolaeva, K. I. Polyakova, A. G. Fisun, K. A. Kokushkin | ||
| "... (QALYs), adverse events, and other clinical outcomes. The search for the relevant information ..." | ||
| Vol 6, No 1 (2013) | THE FEATURES OF METHODOLOGY FOR PHARMACOECONOMICS ANALYSIS OF VACCINATION | Abstract similar documents |
| A. Yu. Kulikov, Yu. L. Akimova | ||
| "... вакцинопрофилактики. Приведены критерии выбора показателей эффективности для различных типов вакцин, расчеты затрат на ..." | ||
| Vol 8, No 2 (2015) | ASSESSMENT OF ECONOMIC EFFICIENCY OF APPLICATION OF RALTEGRAVIR BY PATIENTS WITHOUT EXPERIENCE OF TYPE 1 HIV INFECTION THERAPY IN RUSSIA | Abstract similar documents |
| Elamin H. Elbasha, Elena Aleksandrovna Pyadushkina, Maria Vladimirovna Avxentyeva, Alexander Gennadievich Tolkushin, Maxim Yurievich Frolov | ||
| "... анализ «затраты-полезность» в соответствии с рекомендациями Рабочей группы по оценке затратной ..." | ||
| Vol 10, No 4 (2017) | THE STATE GUARANTEES PROGRAM OF FREE MEDICAL CARE: APPROACHES TO STANDARDIZE THE COSTS OF MEDICAL CARE | Abstract similar documents |
| Yu. A. Ledovskikh, E. V. Semakova, M. V. Avksent’eva | ||
| "... . Структура стандарта обеспечивает возможность расчета затрат на реализацию ПГГ, однако опыт работы над ..." | ||
| Vol 7, No 3 (2014) | ASSESSMENT OF NECESSARY FINANCIAL EXPENSES ON THE DRUG SUPPLY OF THE PATIENTS WITH ORPHAN DISEASES IN THE RUSSIAN FEDERATION | Abstract similar documents |
| M. V. Sura, K. V. Gerasimova, V. V. Omelyanovskiy, M. V. Avksentyeva | ||
| "... в статье представлены результаты расчета необходимых финансовых затрат на лекарственное ..." | ||
| Vol 6, No 4 (2013) | Pharmacoeconomical assessment of сerebrolysin in the treatment of the acute disturbances of cerebral circulation | Abstract similar documents |
| A. Yu. Kulikov, L. A. Komarov | ||
| "... церебролизина для лечения ОНМК по ишемическому типу позволяет сэкономить примерно 1,47 млрд руб. в год в расчете ..." | ||
| Vol 8, No 4 (2015) | HEALTHCARE SPENDING EFFICIENCY IN RUSSIAN REGIONS | Abstract similar documents |
| N. A. Avxentyev, V. M. Baydin, O. A. Zarubina, N. N. Sisigina, S. A. Kulkova | ||
| "... влияния внешних факторов; 3) расчет скорректированной оценки эффективности без учета влияния внешних ..." | ||
| Vol 7, No 2 (2014) | THE ANALYSIS OF THE LIPETSK PHARMACEUTICAL MARKET OF NASAL GLUCOCORTICOSTEROID | Abstract similar documents |
| K. V. Danilova, I. M. Razdorskaya | ||
| "... концептуальный подход, включающий анализ производственного признака, стоимостной анализ, методика расчета ..." | ||
| Vol 8, No 4 (2015) | PHARMACOECONOMIC EVALUATION OF INFLUENZA AND PNEUMOCOCCAL VACCINATION IN EMPLOYEES OF THE JOINT STOCK COMPANY "RUSSIAN RAILWAYS" (JSCO "RZD") ON INVESTMENT FOR THE EMPLOYER | Abstract similar documents |
| D. A. Zhukov | ||
| "... (если необходимо)) и проведением процедуры Мараскуило. Расчеты выполнены в Microsoft Excel (прикладные ..." | ||
| Vol 9, No 1 (2016) | PHARMACOECONOMIC STUDY OF LENVIMA (LENVATINIB) IN ADVANCED PROGRESSIVE RADIO IODINE REFRACTORY DIFFERENTIATED THYROID CANCER IN THE RUSSIAN FEDERATION | Abstract similar documents |
| M. Yu. Frolov, V. A. Rogov | ||
| "... анализ влияния на бюджет. Расчеты проводились в модели, построенной в Microsoft Excel. В анализе «затраты ..." | ||
| Vol 10, No 1 (2017) | EVALUATION OF DRUG THERAPY IN PROGRESSING DIFFERENTIATED THYROID CANCER REFRACTORY TO RADIOACTIVE IODINE IN PATIENTS RESIDING IN THE RUSSIAN FEDERATION : PHARMACOECONOMIC ASPECTS | Abstract similar documents |
| M. Yu. Frolov, V. A. Rogov | ||
| "... . Материалы и методы. Выполнен анализ влияния на бюджет (АВБ) и анализ «затраты-эффективность». Расчеты ..." | ||
| Vol 12, No 3 (2019) | Overview of the existing opportunities and limitations of the state guarantees program for provision of free medical care to citizens | Abstract similar documents |
| D. V. Fedyaev , R. V. Gostishchev , V. A. Lemeshko , O. I. Ivakhnenko | ||
| "... гарантий применяются ограниченно. Расчет подушевого норматива финансирования субъекта РФ зависит только от ..." | ||
| Vol 5, No 3 (2012) | PHARMACOECONOMIC STUDY OVER USE OF ANTICHOLINERGIC BRONCHODILATORS (SPIRIVA AND ATROVENT) FOR TREATMENT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE | Abstract similar documents |
| A. U. Kulikov, I. A. Komarov | ||
| "... «влияния на бюджет» и расчета показателя «упущенных возможностей». ..." | ||
| Vol 7, No 3 (2014) | PHARMACOECONOMIC ANALYSIS OF THE USE OF OXALIPLATIN CHEMOTHERAPY FOR COLORECTAL CANCER.REAL (ACTUAL) CLINICAL PRACTICE DATA | Abstract similar documents |
| A. V. Pavlysh, A. S. Kolbin, A. R. Kasimova | ||
| "... расчет прямых медицинских, прямых немедицинских и косвенных затрат. Применялись три торговых наименования ..." | ||
| Vol 7, No 4 (2014) | MODELING IN CLINICO-ECONOMIC ANALYSIS OF MEDICAL ORGANIZATIONAL TECHNOLOGIES | Abstract similar documents |
| M. A. Shapovalova, A. R. Umerova, V. A. Bondarev, L. R. Koretskaya | ||
| "... древо решений и модель Маркова мы применили для проведения расчета ожидаемых затрат при сравнении ..." | ||
| Vol 8, No 2 (2015) | CLINICAL AND ECONOMIC ANALYSIS OF THE USE OF DIFFERENT TYPES OF SYSTEMS OF VENOUS ACCESS IN THE TREATMENT OF CHILDREN WITH CANCER | Abstract similar documents |
| Maksim Yur'evich Rykov, Vladimir Georgievich Polyakov | ||
| "... имплантируемых венозных порт-систем у 2262 детей в возрасте от 2 мес. до 17 лет. Для расчетов затрат были взяты ..." | ||
| Vol 8, No 2 (2015) | PHARMACOECONOMIC STUDIES TREATMENT OF PATIENTS WITH INJURIES IN THE DEPARTMENT OF ANESTHESIOLOGY AND RESUSCITATION WITH METHODS ANALYSIS THE COST OF ILLNESS | Abstract similar documents |
| Anton Alexandrovich Kasatkin | ||
| "... болезни, включающий расчет прямых медицинских затрат на медицинские услуги, лекарственные препараты ..." | ||
| Vol 9, No 2 (2016) | METASTATIC COLORECTAL TREATMENT COSTS OF USING TARGETED DRUGS IN SECOND AND FURTHER LINES THERAPY | Abstract similar documents |
| N. A. Avxentyev, E. V. Derkach, E. A. Pyadushkina, M. D. Ter-Ovanesov | ||
| "... , что расходы на один месяц лечения регорафенибом в расчете на одного пациента составляют около 255 тыс ..." | ||
| Vol 8, No 4 (2015) | THE COST OF NUTRITION ALTERNATIVES FOR PREMATURE INFANTS IN RUSSIA | Abstract similar documents |
| K. V. Gerasimova, M. V. Avxentyeva, I. A. Belyaeva | ||
| "... жидкой искусственной смеси вместо сухой. Выполнен анализ чувствительности результатов расчетов к ..." | ||
| Vol 12, No 3 (2019) | Comorbidity in elderly patients with atrial fibrillation affects the “cost of illness” | Abstract similar documents |
| S. V. Malchikova , N. S. Maksimchuk-Kolobova, M. V. Kazakovtseva | ||
| "... Geriatrics) и критерия Чарлсона. В расчете «стоимости болезни» учитывали только прямые затраты. Результаты ..." | ||
| Vol 9, No 1 (2016) | PHARMACOECONOMIC SUBSTANTIATION OF APPLICATION OF GENETICALLY ENGINEERED BIOLOGICAL AGENTS IN OUT-PATIENT CONDITIONS | Abstract similar documents |
| O. Yu. Korennova, L. V. Shukil', S. N. Mal'tsev, I. A. Klinyshkov, N. M. Leganova, E. A. Turusheva, T. V. Kropotina | ||
| "... круглосуточного и дневного стационаров. Материалы и методы. В основу фармакоэкономических расчетов по методу ..." | ||
| Vol 9, No 3 (2016) | HEALTH ECONOMIC ASSESSMENT OF ANTIRHEUMATIC DRUGS IN PATIENTS WITH REUMATHOID ARTHRITIS PROGRESSED AFTER METOTREXATE | Abstract similar documents |
| A. S. Kolbin, A. A. Kurylev, M. A. Proskurin, Yu. E. Balykina | ||
| "... фармакоэкономический анализ с расчетом прямых затрат и анализом эффективности затрат. Критерием эффективности терапии ..." | ||
| Vol 10, No 1 (2017) | BIOLOGICAL THERAPY IN ADULT PATIENTS WITH ULCERATIVE COLITIS AND CROHN’S DISEASE: BUDGET IMPACT ANALYSIS | Abstract similar documents |
| E. A. Pyadushkina | ||
| "... ингибиторов ФНО-α. Материалы и методы. Для расчетов использованы статистические данные, литературные ..." | ||
| Vol 10, No 4 (2017) | EVALUATING THE USE OF HOSPITAL BED CAPACITY IN MEDICAL ORGANIZATIONS | Abstract similar documents |
| I. A. Zheleznyakova, L. A. Kovaleva, T. A. Khelisupali, M. A. Voinov, V. V. Omel’yanovskii | ||
| "... фонда в статье произведены расчеты и сравнения результатов по основным показателям эффективности ..." | ||
| Vol 11, No 4 (2018) | Clinical and economic studies on pharmacotherapy of malignant neoplasms: the modeling approach | Abstract similar documents |
| A. G. Tolkushin, S. K. Zyryanov, N. L. Pogudina, M. V. Davydovskaya | ||
| "... метода экстраполяции. Анализ затрат включает расчет стоимости рассматриваемых лекарственных препаратов ..." | ||
| Vol 12, No 1 (2019) | Economic consequences of healthcare optimization for IBD patients in the Republic of Tatarstan | Abstract similar documents |
| T. P. Bezdenezhnykh, D. V. Fedyaev, G. R. Khachatryan, G. G. Arutyunov, K. V. Gerasimova | ||
| "... результатов исследования к колебаниям значений исходных параметров. Результаты расчетов наиболее чувствительны ..." | ||
| Vol 6, No 4 (2013) | Pharmacoeconomic study of nutrition support in the conditions of current health care system in Russia | Abstract similar documents |
| I. A. Metelkin, R. I. Yagudina | ||
| "... : при проведении фармакоэкономического исследования все расчеты производились для трех групп пациентов в ..." | ||
| Vol 8, No 4 (2015) | CLINICAL AND ECONOMIC EVALUATION OF THROMBOPOIETIN RECEPTOR AGONISTS IN THE TREATMENT OF CHRONIC IDIOPATHIC THROMBOCYTOPENIC PURPURA IN ADULTS | Abstract similar documents |
| E. A. Pyadushkina, M. Yu. Frolov, M. V. Avksentyeva | ||
| "... во всех регионах России. Исследование проводилось в период с сентября по декабрь 2015 г. Для расчетов ..." | ||
| 1 - 50 of 57 Items | 1 2 > >> | |
Search tips:
- Search terms are case-insensitive
- Common words are ignored
- By default articles containing any term in the query are returned (i.e., OR is implied)
- Make sure that a word exists in an article by prefixing it with +; e.g., +journal +access scholarly academic
- Combine multiple words with AND to find articles containing all terms; e.g., education AND research
- Exclude a word by prefixing it with - or NOT; e.g., online -politics or online NOT politics
- Search for an exact phrase by putting it in quotes; e.g., "open access publishing". Hint: Quoting Chinese or Japanese words will help you to find exact word matches in mixed-language fields, e.g. "中国".
- Use parentheses to create more complex queries; e.g., archive ((journal AND conference) NOT theses)
